FDA launches real-time clinical trials to speed up drug approvals

The FDA has started receiving live data from clinical trials for the first time in the agency's history. Two pharmaceutical companies are now sending safety and effectiveness information directly to regulators as their studies progress, rather than waiting months or years to compile final reports.

This marks a significant shift in how drugs get tested and approved in the United States. The agency also announced plans for a broader pilot program this summer, seeking input from the industry on how to expand real-time monitoring across more trials.

How will it work?

The current system creates substantial delays in drug development. Companies typically collect data from trial sites, analyze it internally, then submit reports to the FDA in batches. This process can take years before regulators see critical safety signals or effectiveness data.

Real-time clinical trials change this by streaming key information directly to FDA scientists as studies unfold. The agency has established specific criteria with each company about what data gets shared and when.

Two trials are already operational:

• AstraZeneca is running a Phase 2 study called TRAVERSE for mantle cell lymphoma patients, involving MD Anderson Cancer Center and University of Pennsylvania
• Amgen is conducting a Phase 1b trial called STREAM-SCLC for small cell lung cancer patients

The FDA has successfully received and validated data signals from AstraZeneca's trial through a platform called Paradigm Health, proving the technical framework works.

Why does it matter?

The change could significantly accelerate how quickly promising treatments reach patients. Currently, there are often long gaps between different phases of clinical trials while companies prepare data and wait for FDA review.

"For 60 years, we've been conducting clinical trials in the same way, where key data signals can take years to reach the FDA," said FDA Commissioner Marty Makary. "The lag time can delay regulatory decisions unnecessarily and slow down the drug development timeline."

Real-time monitoring also improves safety oversight. If serious side effects emerge during a trial, regulators can spot problems immediately rather than discovering them months later in a final report.

The FDA's ultimate goal is "continuous trials" where different phases of drug testing flow seamlessly together without the current stop-and-start approach.

The context

This initiative reflects broader efforts to modernize clinical research using artificial intelligence and advanced data analytics. The pharmaceutical industry has been discussing real-time trials for years, but technical and regulatory barriers have prevented widespread adoption.

Early-phase clinical trials are particularly problematic in the current system. They often involve small patient populations and high uncertainty, making quick decision-making crucial. Yet the traditional approach can leave promising treatments stuck in development limbo for extended periods.

The FDA is accepting public comments on its pilot program design until May 29, 2026. The agency plans to announce final selection criteria in July and complete pilot selections in August, indicating they want to move quickly on expanding the program.

Chief AI Officer Jeremy Walsh emphasized the patient impact: "We have to consider our processes from the standpoint of a patient awaiting a potentially powerful treatment."